OSI Pharmaceuticals to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13, 2009

  
    
  
  
    
      OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Colin 
      Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals, will 
      present at the JP Morgan Conference in San Francisco, CA on Tuesday, 
      January 13, 2009 at 3:30 p.m. (Pacific Time). Dr. Goddard will provide 
      an overview on the Company’s product portfolio and business developments.
    
    
      The presentation will be webcast live and may be accessed by visiting 
      OSI’s website at www.osip.com. 
      A replay of the webcast will also be available on the Company’s website 
      until January 27, 2009.
    
    
      About OSI Pharmaceuticals
    
    
      OSI Pharmaceuticals is committed to "shaping medicine and changing 
      lives" by discovering, developing and commercializing high-quality and 
      novel pharmaceutical products designed to extend life and/or improve the 
      quality of life for patients with cancer and diabetes/obesity. The 
      Company’s oncology programs are focused on developing molecular targeted 
      therapies designed to change the paradigm of cancer care. OSI’s 
      diabetes/obesity efforts are committed to the generation of novel, 
      targeted therapies for the treatment of type 2 diabetes and obesity. 
      OSI's flagship product, Tarceva® (erlotinib), is the first 
      drug discovered and developed by OSI to obtain FDA approval and the only 
      EGFR inhibitor to have demonstrated the ability to improve survival in 
      both non-small cell lung cancer and pancreatic cancer patients in 
      certain settings. OSI markets Tarceva through partnerships with 
      Genentech, Inc. in the United States and with Roche throughout the rest 
      of the world. For additional information about OSI, please visit http://www.osip.com.
    
    
      This news release contains forward-looking statements. These 
      statements are subject to known and unknown risks and uncertainties that 
      may cause actual future experience and results to differ materially from 
      the statements made. Factors that might cause such a difference 
      include, among others, the completion of clinical trials, the FDA review 
      process and other governmental regulation, OSI's and its collaborators' 
      abilities to successfully develop and commercialize drug candidates, 
      competition from other pharmaceutical companies, the ability to 
      effectively market products, and other factors described in OSI 
      Pharmaceuticals' filings with the Securities and Exchange Commission.